Page last updated: 2024-10-31

mitotane and Local Neoplasm Recurrence

mitotane has been researched along with Local Neoplasm Recurrence in 54 studies

Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.

Research Excerpts

ExcerptRelevanceReference
"The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy."8.98Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018)
"Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma."8.90Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014)
"Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent."7.96Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020)
"In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)."7.85Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017)
"Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)."7.79Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013)
"Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma."7.74Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007)
" IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks."6.79The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014)
"Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control."5.62Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021)
"Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index."5.51Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019)
"By treatment with Mitotane in a dose aiming at completely destroying the adrenal cortex, a complete disappearance of the tumor as well as a dramatic reduction of the size of the metastases could be achieved."5.30[Mitotane treatment in a dog with a recurring adrenocortical carcinoma--a case report]. ( Flückiger, M; Gardelle, O; Keiser, M; Reusch, C, 1999)
"Treatment with mitotane was started shortly after surgical removal of the tumor (three patients) or the tumor and multiple lung metastasis (one patient)."5.30Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? ( Arad, E; Best, LA; Dickstein, G; Nativ, O; Shechner, C, 1998)
"A 58-year-old man had adrenocortical carcinoma in the right adrenal gland."5.30Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999)
"Adrenal cortical carcinoma is a rare tumour with a poor prognosis."5.28Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. ( Cheah, JS; Chong, PY; Lim, MC; Tan, YO, 1990)
"Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy for patients with early-stage adrenocortical carcinoma (ACC)."5.22Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? ( Abate, A; Berruti, A; Cosentini, D; Cremaschi, V; Grisanti, S; Laganà, M; Rossini, E; Sigala, S; Tamburello, M; Turla, A, 2022)
"A recent nonrandomized interinstitutional study reported that adjuvant mitotane following surgery for adrenocortical carcinoma (ACC) was associated with decreased recurrence."5.14Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. ( Callender, GG; Evans, DB; Grubbs, EG; Lee, JE; Perrier, ND; Phan, AT; Xing, Y, 2010)
"The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy."4.98Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018)
"Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma."4.90Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014)
"Mitotane has been used for 50 years as the first-line drug in the treatment of disseminated adrenocortical carcinoma."4.86[Mitotane in the treatment of adrenal carcinoma]. ( Sane, T, 2010)
"A retrospective analysis showing that adjuvant mitotane may prolong recurrence-free survival in a large cohort of patients with radically resected adrenocortical carcinoma has recently been published."4.84Adjunctive treatment of adrenocortical carcinoma. ( Berruti, A; Terzolo, M, 2008)
"Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent."3.96Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020)
"In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)."3.85Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017)
"Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)."3.79Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013)
"Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma."3.74Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007)
" IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks."2.79The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014)
" The therapeutic range is close and therefore dosage is difficult, mainly based on clinical signs."2.70[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. ( Heilmann, P; Nawroth, PP; Wagner, P; Ziegler, R, 2001)
"Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy."2.49Update in adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M, 2013)
"The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences."1.91The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. ( Basile, V; Berchialla, P; Borin, C; Calabrese, A; Fiori, C; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Terzolo, M; Veltri, A; Volante, M, 2023)
"The prognosis of adrenocortical carcinoma (ACC) is poor but highly variable."1.91Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience. ( Huang, CJ; Lin, LY; Ng, XN; Pan, LH; Yen, CC, 2023)
"Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control."1.62Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021)
"Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index."1.51Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019)
"Adrenocortical carcinoma is a rare and aggressive malignancy with an incidence of 0."1.51A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. ( Ali, A; Anwar, AW; Bakar, MA; Khan, MA; Khan, MS; Tariq, I, 2019)
"Mitotane was administered in 12 (71 %) patients with stage III-IV ACCs with a 5-year survival rate 25 % compared to 20 % in patients who did not receive Mitotane."1.42Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. ( Abdel-Aziz, TE; Mihai, R; Rajeev, P; Sadler, G; Weaver, A, 2015)
"Adrenocortical carcinoma is a rare malignant endocrine neoplasia."1.40Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. ( Else, T; Hammer, GD; Jolly, S; Miller, BS; Sabolch, A; Williams, AR, 2014)
"Median survival in stage II adrenocortical carcinoma (ACC) differs widely in published series ranging between 23 and more than 60 months."1.36Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. ( Agha, A; Allolio, B; Beuschlein, F; Fassnacht, M; Fenske, W; Führer, D; Hahner, S; Johanssen, S; Jurowich, C; Petersenn, S; Quinkler, M; Spahn, M; Weismann, D, 2010)
"In suspected nonmetastatic adrenocortical carcinoma (ACC) a careful preoperative diagnostic work up is needed including comprehensive endocrine analysis as recommended by the European Network for the Study of Adrenal Tumors (http://www."1.36What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? ( Allolio, B; Fassnacht, M, 2010)
"Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease."1.35How is adrenocortical cancer being managed in the UK? ( Aspinall, SR; Bliss, RD; Harrison, BJ; Imisairi, AH; Lennard, TW; Scott-Coombes, D, 2009)
"Mitotane was given to 67 evaluable patients with recurrent ACC."1.34Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. ( Evans, DB; Gonzalez, RJ; Lee, JE; Ng, C; Perrier, ND; Phan, AT; Tamm, EP; Vassilopoulou-Sellin, R, 2007)
"Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation."1.33Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Flentje, M; Hahner, S; Kenn, W; Koschker, AC; Polat, B, 2006)
"By treatment with Mitotane in a dose aiming at completely destroying the adrenal cortex, a complete disappearance of the tumor as well as a dramatic reduction of the size of the metastases could be achieved."1.30[Mitotane treatment in a dog with a recurring adrenocortical carcinoma--a case report]. ( Flückiger, M; Gardelle, O; Keiser, M; Reusch, C, 1999)
"A 58-year-old man had adrenocortical carcinoma in the right adrenal gland."1.30Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999)
"Treatment with mitotane was started shortly after surgical removal of the tumor (three patients) or the tumor and multiple lung metastasis (one patient)."1.30Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? ( Arad, E; Best, LA; Dickstein, G; Nativ, O; Shechner, C, 1998)
"Adrenocortical carcinoma is a rare and aggressive disease with a poor prognosis."1.29Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. ( Guinee, VF; Hess, KR; Klein, MJ; Samaan, NA; Schultz, PN; Taylor, SH; Vassilopoulou-Sellin, R, 1993)
"Mitotane therapy was ineffective at controlling tumor growth."1.28Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. ( Jensen, JC; Norton, JA; Pass, HI; Sindelar, WF, 1991)
"Adrenocortical carcinoma is a rare disease which is primarily approached surgically."1.28Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. ( Brady, LW; Markoe, AM; Micaily, B; Serber, W, 1991)
"Adrenal cortical carcinoma is a rare tumour with a poor prognosis."1.28Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. ( Cheah, JS; Chong, PY; Lim, MC; Tan, YO, 1990)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19904 (7.41)18.7374
1990's12 (22.22)18.2507
2000's11 (20.37)29.6817
2010's21 (38.89)24.3611
2020's6 (11.11)2.80

Authors

AuthorsStudies
Terzolo, M9
Fassnacht, M11
Cremaschi, V1
Abate, A1
Cosentini, D1
Grisanti, S2
Rossini, E1
Laganà, M1
Tamburello, M1
Turla, A1
Sigala, S1
Berruti, A7
Calabrese, A2
Puglisi, S2
Borin, C1
Basile, V3
Perotti, P3
Pia, A2
Berchialla, P2
Volante, M5
Fiori, C1
Porpiglia, F3
Veltri, A2
Reimondo, G3
Pan, LH1
Yen, CC1
Huang, CJ1
Ng, XN1
Lin, LY1
Weigand, I1
Altieri, B1
Lacombe, AMF1
Kircher, S1
Landwehr, LS1
Schreiner, J1
Zerbini, MCN1
Ronchi, CL1
Megerle, F1
Canu, L1
Paiva, I2
Della Casa, S1
Sbiera, S1
Fragoso, MCBV1
Kroiss, M4
Ohmoto, A1
Shigematsu, Y1
Fukuda, N1
Wang, X1
Urasaki, T1
Hayashi, N1
Sato, Y1
Nakano, K1
Yunokawa, M1
Ono, M1
Komai, Y1
Numao, N1
Yuasa, T1
Yonese, J1
Tomomatsu, J1
Inamura, K1
Takahashi, S1
Pulzer, A2
Claps, M1
Daffara, F3
Loli, P2
Mannelli, M2
Boscaro, M1
Arvat, E2
Tiberio, G1
Hahner, S4
Zaggia, B3
Shuayb, M1
Das, A1
Uddin, MN1
Tang, Y1
Liu, Z1
Zou, Z1
Liang, J1
Lu, Y1
Zhu, Y1
Saba, L1
Khan, MS1
Ali, A1
Tariq, I1
Khan, MA1
Bakar, MA1
Anwar, AW1
Freire, DS1
Siqueira, SA1
Zerbini, MC1
Wajchenberg, BL1
Corrêa-Giannella, ML1
Lucon, AM1
Pereira, MA1
Baudin, AE1
Ardito, A1
Leboulleux, S1
Feelders, RA1
deVries, JH1
De Francia, S2
Haak, HR1
Allolio, B7
Al Ghuzlan, A1
Else, T2
Williams, AR1
Sabolch, A1
Jolly, S1
Miller, BS1
Hammer, GD2
Allasino, B1
Lerario, AM1
Worden, FP1
Ramm, CA1
Hesseltine, EA1
Hasseltine, EA1
Stadler, WM1
Shah, MH1
Agamah, E1
Rao, K1
Abdel-Aziz, TE1
Rajeev, P1
Sadler, G1
Weaver, A1
Mihai, R2
Ranvier, GG1
Inabnet, WB1
Baur, J1
Schedelbeck, U1
Bluemel, C1
Wild, V1
Steger, U1
Guelho, D1
Vieira, A1
Carrilho, F1
Aspinall, SR1
Imisairi, AH1
Bliss, RD1
Scott-Coombes, D1
Harrison, BJ1
Lennard, TW1
Grubbs, EG1
Callender, GG1
Xing, Y1
Perrier, ND2
Evans, DB3
Phan, AT2
Lee, JE3
Johanssen, S1
Fenske, W2
Weismann, D1
Agha, A1
Beuschlein, F1
Führer, D1
Jurowich, C2
Quinkler, M1
Petersenn, S1
Spahn, M1
Sane, T1
Reibetanz, J1
Deutschbein, T1
Gasser, M1
Germer, CT1
Kvacheniuk, AN1
Brauckhoff, M1
Dralle, H2
Martins, AC1
Cologna, AJ1
Tucci, S1
Suaid, HJ1
Falconi, RA1
Polat, B1
Koschker, AC2
Kenn, W1
Flentje, M1
Angeli, A1
Tauchmanova, L1
Conton, PA1
Rossetto, R1
Buci, L1
Sperone, P1
Grossrubatscher, E1
Bollito, E1
Papotti, M1
Saeger, W1
Ambrosi, B1
Lombardi, G1
Bruzzi, P1
Mantero, F1
Dogliotti, L1
Carmona-Bayonas, A1
Soler, IO1
Gómez, FI1
Billalabeitia, EG1
Saura, HP1
Tafalla, MS1
Díaz, MP1
Machens, A1
Gonzalez, RJ1
Tamm, EP1
Ng, C1
Vassilopoulou-Sellin, R3
Schteingart, DE1
Motazedi, A1
Noonan, RA1
Thompson, NW1
Lobel, H1
Rudnicki, K1
Zahavi, I1
Berger, DH1
el-Naggar, AK1
Hickey, RC1
Gagel, RF1
Burgess, MA1
Favia, G1
Lumachi, F1
Carraro, P1
D'Amico, DF1
Guinee, VF1
Klein, MJ1
Taylor, SH1
Hess, KR1
Schultz, PN1
Samaan, NA1
Kasperlik-Załuska, AA1
Migdalska, BM1
Makowska, AM1
Dickstein, G1
Shechner, C1
Arad, E1
Best, LA1
Nativ, O1
Keiser, M1
Flückiger, M1
Gardelle, O1
Reusch, C1
Seki, M1
Nomura, K1
Hirohara, D1
Kanazawa, M1
Sawada, T1
Takasaki, K1
Demura, H1
Heilmann, P1
Wagner, P1
Nawroth, PP1
Ziegler, R1
Pommier, RF1
Brennan, MF1
van Aalderen, W1
van Seters, AP1
Backer, ET1
Chang, PC1
van Krieken, JH1
Moolenaar, AJ1
Jensen, JC1
Pass, HI1
Sindelar, WF1
Norton, JA1
Markoe, AM1
Serber, W1
Micaily, B1
Brady, LW1
Lim, MC1
Tan, YO1
Chong, PY1
Cheah, JS1
Donckier, JE1
Michel, LA1
Berbinschi, A1
De Coster, PM1
De Plaen, JF1
Ketelslegers, JM1
Buysschaert, M1
Levy, JM1
Lutz, P1
Wagner, C1
Sauer, P1
Seiller, F1
Fischbach, M1
Segura, N1
Sauvage, P1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence[NCT03723941]Phase 3240 participants (Anticipated)Interventional2018-07-01Recruiting
Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry[NCT00453674]1,000 participants (Anticipated)Observational2003-01-31Recruiting
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence[NCT00777244]Phase 3200 participants (Anticipated)Interventional2008-04-30Recruiting
Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy[NCT00786110]Phase 230 participants (Anticipated)Interventional2008-04-30Recruiting
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma[NCT02015026]67 participants (Actual)Observational2013-12-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

12 reviews available for mitotane and Local Neoplasm Recurrence

ArticleYear
ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.
    European journal of endocrinology, 2022, Sep-01, Volume: 187, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Humans;

2022
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C

2022
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
    BioMed research international, 2018, Volume: 2018

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2018
Update in adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Animals; Antineoplastic Agents,

2013
Practical treatment using mitotane for adrenocortical carcinoma.
    Current opinion in endocrinology, diabetes, and obesity, 2014, Volume: 21, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2014
Diagnosis, treatment and outcome of adrenocortical cancer.
    The British journal of surgery, 2015, Volume: 102, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hor

2015
Surgical management of adrenocortical carcinoma.
    Endocrinology and metabolism clinics of North America, 2015, Volume: 44, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2015
[Mitotane in the treatment of adrenal carcinoma].
    Duodecim; laaketieteellinen aikakauskirja, 2010, Volume: 126, Issue:17

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan

2010
[German adrenocortical carcinoma registry. Surgical therapy results and follow-up treatment].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2012, Volume: 83, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Aftercare; Antineoplastic Agents, Hormonal; Chemotherapy, A

2012
[Recurrent operations on the adrenal glands].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2005, Volume: 76, Issue:3

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Anti

2005
Adjunctive treatment of adrenocortical carcinoma.
    Current opinion in endocrinology, diabetes, and obesity, 2008, Volume: 15, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemother

2008
Adrenocortical carcinoma. Our experience.
    Minerva endocrinologica, 1995, Volume: 20, Issue:1

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adult; Aged; Antineoplastic Combined Chemothera

1995

Trials

3 trials available for mitotane and Local Neoplasm Recurrence

ArticleYear
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
    Hormones & cancer, 2014, Volume: 5, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies,

2014
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
    Annals of surgical oncology, 2010, Volume: 17, Issue:1

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2010
[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
    Medizinische Klinik (Munich, Germany : 1983), 2001, Jul-15, Volume: 96, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe

2001

Other Studies

39 other studies available for mitotane and Local Neoplasm Recurrence

ArticleYear
The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients.
    European journal of endocrinology, 2023, Jan-10, Volume: 188, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan

2023
Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Mitotane; Neoplasm Recurrence, L

2023
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    The Journal of clinical endocrinology and metabolism, 2020, 08-01, Volume: 105, Issue:8

    Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineopla

2020
Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
    Endocrine journal, 2021, Dec-28, Volume: 68, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Japan;

2021
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2017, Apr-01, Volume: 102, Issue:4

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80

2017
Long-term survival in recurrent adrenocortical cancer.
    BMJ supportive & palliative care, 2019, Volume: 9, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Adult; Antineoplastic Combined C

2019
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    European journal of endocrinology, 2019, Jun-01, Volume: 180, Issue:6

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2019
A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
    JPMA. The Journal of the Pakistan Medical Association, 2019, Volume: 69, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcino

2019
Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence.
    Clinical endocrinology, 2013, Volume: 79, Issue:4

    Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo

2013
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    European journal of endocrinology, 2013, Volume: 169, Issue:3

    Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo

2013
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:2

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80

2014
Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    World journal of surgery, 2015, Volume: 39, Issue:5

    Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplas

2015
A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma.
    BMC surgery, 2015, Jul-31, Volume: 15

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2015
Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2016, Volume: 63, Issue:5

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Chemothe

2016
How is adrenocortical cancer being managed in the UK?
    Annals of the Royal College of Surgeons of England, 2009, Volume: 91, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2009
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:11

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti

2010
What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
    Clinical endocrinology, 2010, Volume: 73, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Ki-67 Antigen; Mitotane; Neoplasm Recurr

2010
[Analysis of postoperative recurrence of malignant tumors of adrenal glands].
    Klinichna khirurhiia, 2004, Issue:2

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Antineoplastic Agents, Hormonal; Female; Humans; Male

2004
Clinical features and immunoexpression of p53, MIB-1 and proliferating cell nuclear antigen in adrenal neoplasms.
    The Journal of urology, 2005, Volume: 173, Issue:6

    Topics: Adenoma; Adolescent; Adrenal Gland Neoplasms; Adrenal Glands; Adrenalectomy; Adult; Antineoplastic C

2005
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe

2006
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Tailored hormonal therapy in secretory adrenocortical cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang

2007
Adjuvant mitotane in adrenocortical carcinoma.
    The New England journal of medicine, 2007, Sep-20, Volume: 357, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
    Surgery, 2007, Volume: 142, Issue:6

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Child; Child, Pr

2007
Treatment of adrenal carcinomas.
    Archives of surgery (Chicago, Ill. : 1960), 1982, Volume: 117, Issue:9

    Topics: Adrenal Gland Neoplasms; Adult; Carcinoma; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mi

1982
[Adrenal cortical carcinoma].
    Harefuah, 1982, Volume: 103, Issue:3-4

    Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adult; Female; Humans; Mitotane; Neoplasm Recurre

1982
Surgical management, DNA content, and patient survival in adrenal cortical carcinoma.
    Surgery, 1995, Volume: 118, Issue:6

    Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Aneuploidy; Carcinoma; Combined Modality

1995
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer.
    Cancer, 1993, May-15, Volume: 71, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adult; Aged; Carcinoma; Combined Modality Therapy; Female; Humans; Male; M

1993
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later.
    Cancer, 1996, Oct-01, Volume: 78, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Chemotherapy, Adjuvant; Female; Follow-Up

1996
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Agents, Hormonal; Carcinoma; Chemotherapy, Adj

1998
[Mitotane treatment in a dog with a recurring adrenocortical carcinoma--a case report].
    Schweizer Archiv fur Tierheilkunde, 1999, Volume: 141, Issue:6

    Topics: Adrenal Cortex Neoplasms; Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cushing Syndrome; Dog

1999
Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
    Endocrine-related cancer, 1999, Volume: 6, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Dehydroepiandro

1999
An eleven-year experience with adrenocortical carcinoma.
    Surgery, 1992, Volume: 112, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adult; Carcinoma; Combined Modality Therapy; Fema

1992
A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications.
    The Netherlands journal of medicine, 1992, Volume: 41, Issue:3-4

    Topics: Adrenal Gland Neoplasms; Carcinoma; Carcinosarcoma; Combined Modality Therapy; Female; Humans; Lung

1992
Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy.
    Archives of surgery (Chicago, Ill. : 1960), 1991, Volume: 126, Issue:4

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

1991
Radiation therapy for adjunctive treatment of adrenal cortical carcinoma.
    American journal of clinical oncology, 1991, Volume: 14, Issue:2

    Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Carcinoma; Child; Combined Modality Therapy; Femal

1991
Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
    Annals of the Academy of Medicine, Singapore, 1990, Volume: 19, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocorticotropic Hormone; Carcinoma; Cortisone; Female; Humans; Hydroco

1990
Late recurrence of operated adrenocortical carcinoma: atrial natriuretic factor before and after treatment with mitotane.
    Surgery, 1989, Volume: 105, Issue:5

    Topics: Adrenal Gland Neoplasms; Atrial Natriuretic Factor; Carcinoma; Combined Modality Therapy; Cushing Sy

1989
[Favorable outcome of a recurring malignant adrenocortical tumor under O,P'-DDD therapy].
    Annales de pediatrie, 1985, Volume: 32, Issue:6

    Topics: Adrenal Cortex Neoplasms; Child, Preschool; Combined Modality Therapy; Humans; Male; Mitotane; Neopl

1985